FindTrial
Sign In

A multicenter study of induction and consolidation chemotherapy in patients with acute myeloid leukemia with double mutations of CEBPA

A multicenter study of induction and consolidation chemotherapy in patients with acute myeloid leukemia with double mutations of CEBPA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034412
Enrollment
Unknown
Registered
2020-07-04
Start date
2020-07-23
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Group A:IA scheme
Group B:DA scheme

Sponsors

Shanxi Bethune Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-60 years, both male and female; 2) The diagnosis of acute myeloid leukemia (AML) combined with double mutation of CEBPA was performed according to WHO criteria. 3) The ECOG-ps score of the eastern oncology collaboration group was 0-2. 4) Obtain informed consent signed by patients or family members.

Exclusion criteria

Exclusion criteria: 1) Accompanied by cerebral hemorrhage; 2) Pregnancy; 3) Mental illness or other conditions that cannot be carried out as planned; 4) Severe arrhythmia, abnormal ECG (QT > 500ms); 5) Other situations considered unsuitable by the researcher.

Design outcomes

Primary

MeasureTime frame
Complete remission rate;Relapse Rate;Event free survival;????? Outcome: Overall survival;—

Secondary

MeasureTime frame
Peripheral blood primitive cell count in agranulocytosis;—

Countries

China

Contacts

Public ContactTao Wang
wangtao99699@163.com+86 13835175119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026